US approvals of high-risk medical devices are way down.
A scorchingly positive adcom was somewhat unexpected given the FDA’s scepticism in the briefing documents.
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Device deal making is back in a big way, despite the munificence of venture funds.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Shareholders are rewarding the kinds of companies they punished a year ago.